Pandemic Flu Prep: An Interview With Novartis Vaccines Chief Andrin Oswald
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis recently produced its first batch of H1N1 vaccine, but winning approval for a cell-based vaccine could prove challenging in the U.S.
You may also be interested in...
Back To School: Catch Up On Our Executive Interviews
Recent Q&As explore a range of topics including biomarkers and translational medicine with execs from AstraZeneca, Merck, and Interleukin Genetics; diabetes and FDA's cardiovascular safety guidance; and Millennium Pharmaceuticals' first year as the Takeda Oncology company.
Back To School: Catch Up On Our Executive Interviews
Recent Q&As explore a range of topics including biomarkers and translational medicine with execs from AstraZeneca, Merck, and Interleukin Genetics; diabetes and FDA's cardiovascular safety guidance; and Millennium Pharmaceuticals' first year as the Takeda Oncology company.
China's Sinovac, With High-level Government Backing, Could Win Global Race To Market A/H1N1 Vaccine
BEIJING - With the strong support of China's central government and Beijing health authorities, leading vaccine maker Sinovac Biotech could become the first to cross the finish line in the worldwide race to produce a defense to the A/H1N1 pandemic